Mucosal and Cellular Immune Responses to Norwalk Virus

Journal of Infectious Diseases

Volumn 212, Issue 3, 2015, Pages 397-405

  Ramani, Sasirekha ^a   Neill, Frederick H ^a   Opekun, Antone R ^a   Gilger, Mark A ^b,c   Graham, David Y ^a   Estes, Mary K ^a   Atmar, Robert L ^a  

^a Department of Molecular Virology and Microbiology ^*  (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Foundation Surgical Hospital of San Antonio   (United States)

Author keywords

antibody secreting cells; correlate of protection; fecal IgA; IgA; IgG; immune response; memory B cells; Norovirus; Norwalk virus; salivary IgA

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ABDOMINAL CRAMP; ADULT; ANTIBODY SECRETING CELL; ANTIBODY SPECIFICITY; ANTIBODY TITER; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; FECES ANALYSIS; GASTROENTERITIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION SENSITIVITY; MALAISE; MEMORY CELL; MUCOSAL IMMUNITY; NAUSEA; NONHUMAN; NORMAL HUMAN; NORWALK VIRUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SALIVA ANALYSIS; SALIVA LEVEL; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; VOMITING; BLOOD; CALICIVIRUS INFECTION; CHEMISTRY; FECES; IMMUNOLOGY; MONONUCLEAR CELL; SALIVA; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; CALICIVIRIDAE INFECTIONS; FECES; GASTROENTERITIS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; NORWALK VIRUS; SALIVA;

EID: 84938706844     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv053     Document Type: Conference Paper

References (24)

1. Ahmed SM, Hall AJ, Robinson AE, et al. Global prevalence of norovirus in cases of gastroenteritis: A systematic review and meta-analysis. Lancet Infect Dis 2014; 14:725-30.
2. Ramani S, Atmar RL, Estes MK. Epidemiology of human noroviruses and updates on vaccine development. Curr Opin Gastroenterol 2014; 30:25-33.
3. Hall AJ, Lopman BA, Payne DC, et al. Norovirus disease in the United States. Emerg Infect Dis 2013; 19:1198-205.
4. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk Virus illness. New Engl J Med 2011; 365:2178-87.
5. Kavanagh O, Estes MK, Reeck A, et al. Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vaccine Immunol 2011; 18:1187-90.
6. Reeck A, Kavanagh O, Estes MK, et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010; 202:1212-8.
7. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. Cellular and humoral immunity following Snow Mountain virus challenge. J Virol 2005; 79:2900-9.
8. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003; 9:548-53.
9. Okhuysen PC, Jiang X, Ye L, Johnson PC, Estes MK. Viral shedding and fecal IgA response after Norwalk virus infection. J Infect Dis 1995; 171:566-9.
10. Atmar RL, Opekun AR, Gilger MA, et al. Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis 2014; 209:1016-22.
11. Ajami NJ, Barry MA, Carrillo B, et al. Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus. Clin Vaccine Immunol 2012; 19:1980-3.
12. Gaspari MM, Brennan PT, Solomon SM, Elson CO. A method of obtaining, processing, and analyzing human intestinal secretions for antibody content. J Immunol Methods 1988; 110:85-91.
13. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigenspecific memory B cells: A sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286:111-22.
14. Zhang Q, Choo S, Everard J, Jennings R, Finn A. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect Immun 2000; 68:2692-7.
15. Hutson AM, Airaud F, LePendu J, Estes MK, Atmar RL. Norwalk virus infection associates with secretor status genotyped from sera. J Med Virol 2005; 77:116-20.
16. Janeway CA, Travers P, Walport M, Shlomchik M. The mucosal immune system. Immunobiology: The Immune System in Health and Disease. 5th ed. New York: Garland Science, 2001.
17. El-Kamary SS, Pasetti MF, Mendelman PM, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibodysecreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010; 202:1649-58.
18. Ramirez K,Wahid R, Richardson C, et al. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin Immunol 2012; 144:98-108.
19. Patel SM, Rahman MA, Mohasin M, et al. Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh. Clin Vaccine Immunol 2012; 19:842-8.
20. Simmons K, Gambhir M, Leon J, Lopman B. Duration of immunity to norovirus gastroenteritis. Emerg Infect Dis 2013; 19:1260-7.
21. Treanor JJ, Atmar RL, Frey SE, et al. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate-reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis 2014; 210:1763-71.
22. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54:1615-7.
23. Atmar RL, Bernstein DI, Lyon GM, et al. Serological correlates of protection against a GII.4 norovirus. Presented at: 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases, Dublin, Ireland, 2014.
24. Sasaki S, Jaimes MC, Holmes TH, et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007; 81:215-28.